A major review found that cannabinoid receptor agonists and endocannabinoid enzyme inhibitors produce reliable pain relief and offer opioid-sparing effects across preclinical inflammatory and neuropathic pain models, though clinical evidence for enzyme inhibitors remains limited.
Read this if you are interested in how the endocannabinoid system works as a pain treatment target and its potential to reduce opioid dependence.
Cannabinoid approaches offer opioid-sparing effects across preclinical pain models
What the researchers found
This comprehensive review examined the entire endocannabinoid system as a source of pain treatment targets, covering CB1 and CB2 receptors plus the enzymes that make and break down endocannabinoids (FAAH and MAGL).
In preclinical models, cannabinoid receptor agonists and inhibitors of endocannabinoid-regulating enzymes (FAAH and MAGL) produced reliable antinociceptive (pain-reducing) effects across multiple inflammatory and neuropathic pain models.
A particularly notable finding: these compounds offered opioid-sparing effects, meaning they could reduce the amount of opioid medication needed for pain control.
Clinical studies showed that medicinal cannabis or cannabinoid-based medications relieve pain in cancer, multiple sclerosis, and fibromyalgia. However, clinical data had not yet demonstrated analgesic efficacy for FAAH or MAGL inhibitors in human trials.
The gap between strong preclinical results and limited clinical translation for enzyme inhibitors remained a key challenge in the field.
Why it matters
The opioid crisis has created urgent need for alternative pain medications. The endocannabinoid system represents a parallel pain-modulating pathway, and the finding that cannabinoid-based approaches can spare opioid use is particularly significant for patients with chronic pain conditions.
The numbers in context
Key targets: CB1 and CB2 receptors, FAAH enzyme, MAGL enzyme. Clinical efficacy shown for: cancer pain, MS pain, fibromyalgia. Opioid-sparing effects demonstrated in preclinical models.
How the study worked
Comprehensive review of preclinical and clinical evidence on endocannabinoid system targets for pain, covering CB1/CB2 receptor agonists, FAAH inhibitors, and MAGL inhibitors across inflammatory and neuropathic pain models.
What this study cannot tell us
The gap between preclinical promise and clinical results for enzyme inhibitors is a significant concern. Cannabinoid receptor agonists carry side effect profiles including psychoactive effects. Long-term safety data for many of these approaches remains limited. Not all pain conditions were covered equally.
How to read the evidence
This comprehensive review covers extensive preclinical and clinical literature from a high-impact journal (Neuropsychopharmacology), providing strong evidence on the current state of endocannabinoid pain research.
When this study was published
Published in 2018. Clinical trials of endocannabinoid enzyme inhibitors have continued since publication, with mixed results.
The bigger picture
This review maps the entire landscape of endocannabinoid pain targets, revealing both mature areas (CB receptor agonists with clinical evidence) and emerging areas (enzyme inhibitors with strong preclinical but limited clinical evidence). The opioid-sparing potential is perhaps the most significant practical implication for current clinical practice.
Questions still open
- Why have FAAH and MAGL inhibitors failed to translate preclinical success to clinical trials? Can combination approaches (cannabinoids + low-dose opioids) be formalized into clinical protocols? Which chronic pain populations benefit most from cannabinoid-based approaches?
Common questions
Can cannabinoids replace opioids for pain?
Why focus on enzymes rather than just THC?
Read the original research
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(1), 52-79
Citation
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L; Curry, Zachary A; Schurman, Lesley D; Kinsey, Steven G; Lichtman, Aron H. (2018). The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(1), 52-79. https://doi.org/10.1038/npp.2017.204
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- THC and Painkillers: Opioid Interactions and the Harm Reduction Angle
- THC and Muscle Relaxers: What You Need to Know About Combining Them
- THC and Ibuprofen: Safe to Combine? What the Research Says
- Cannabis and Arthritis: What the Research Actually Shows